|
Volumn 19, Issue 2, 2014, Pages 175-176
|
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: A phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERLOTINIB;
FLUORODEOXYGLUCOSE F 18;
PERTUZUMAB;
ANTINEOPLASTIC AGENT;
ERBB2 PROTEIN, HUMAN;
MONOCLONAL ANTIBODY;
PROTEIN KINASE INHIBITOR;
QUINAZOLINE DERIVATIVE;
ARTICLE;
CLINICAL ARTICLE;
COMPUTER ASSISTED TOMOGRAPHY;
DIMERIZATION;
HUMAN;
HUMAN TISSUE;
LOADING DRUG DOSE;
LUNG NON SMALL CELL CANCER;
OVERALL SURVIVAL;
PHASE 2 CLINICAL TRIAL;
PNEUMATOSIS INTESTINALIS;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
UNSPECIFIED SIDE EFFECT;
ANTAGONISTS AND INHIBITORS;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIAL;
DIAGNOSTIC USE;
LUNG NEOPLASMS;
METABOLISM;
MULTIMODAL IMAGING;
PROCEDURES;
RECURRENT DISEASE;
SCINTISCANNING;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, NON-SMALL-CELL LUNG;
FLUORODEOXYGLUCOSE F18;
HUMANS;
LUNG NEOPLASMS;
MULTIMODAL IMAGING;
POSITRON-EMISSION TOMOGRAPHY;
PROTEIN KINASE INHIBITORS;
QUINAZOLINES;
RECEPTOR, ERBB-2;
RECURRENCE;
TOMOGRAPHY, X-RAY COMPUTED;
|
EID: 84894032459
PISSN: 10837159
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.2013-0026 Document Type: Article |
Times cited : (21)
|
References (0)
|